Quantcast
Channel:
Viewing all articles
Browse latest Browse all 64049

MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors

0
0
ROCKVILLE, Md., June 3, 2013 /PRNewswire/ -- MacroGenics, Inc. announced that results of the first-in-human study of margetuximab were reported during an oral abstract session today at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).  Howard A....

Viewing all articles
Browse latest Browse all 64049

Latest Images

Trending Articles





Latest Images